<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To compare the mutational and copy number profiles of primary and metastatic colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>) using both unpaired and paired samples derived from primary and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> sites </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: We performed a multiplatform genomic analysis of 736 fresh frozen <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from 613 patients </plain></SENT>
<SENT sid="2" pm="."><plain>The cohort included 84 patients in whom <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue from both primary and metastatic sites was available and 31 patients with pairs of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> were analyzed for mutations in the KRAS, NRAS, BRAF, PIK3CA, and TP53 genes, with discordant results between paired samples further investigated by analyzing formalin-fixed, paraffin-embedded tissue and/or by 454 sequencing </plain></SENT>
<SENT sid="4" pm="."><plain>Copy number aberrations in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and matched <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> were analyzed by comparative genomic hybridization (CGH) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: TP53 mutations were more frequent in metastatic versus <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> (53.1% v 30.3%, respectively; P &lt; .001), whereas BRAF mutations were significantly less frequent (1.9% v 7.7%, respectively; P = .01) </plain></SENT>
<SENT sid="6" pm="."><plain>The mutational status of the matched pairs was highly concordant (&gt; 90% concordance for <z:hpo ids='HP_0000001'>all</z:hpo> five genes) </plain></SENT>
<SENT sid="7" pm="."><plain>Clonality analysis of array CGH data suggested that multiple <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> or treatment-associated effects were likely etiologies for mutational and/or copy number profile differences between <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: For determining <z:mp ids='MP_0011356'>RAS</z:mp>, BRAF, and PIK3CA mutational status, genotyping of the primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is sufficient for most patients </plain></SENT>
<SENT sid="9" pm="."><plain>Biopsy of a metastatic site should be considered in patients with a history of multiple primary <z:mp ids='MP_0002038'>carcinomas</z:mp> and in the case of TP53 for patients who have undergone interval treatment with radiation or cytotoxic chemotherapies </plain></SENT>
</text></document>